Novartis AG (NVS)
163.07
+0.61
(+0.38%)
USD |
NYSE |
Sep 03, 16:00
163.07
0.00 (0.00%)
After-Hours: 20:00
Novartis Research and Development Expense (TTM) : 11.26B for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 11.26B |
| March 31, 2026 | 11.16B |
| December 31, 2025 | 10.65B |
| September 30, 2025 | 10.34B |
| June 30, 2025 | 9.802B |
| March 31, 2025 | 9.420B |
| December 31, 2024 | 9.353B |
| September 30, 2024 | 8.966B |
| June 30, 2024 | 8.648B |
| March 31, 2024 | 8.674B |
| December 31, 2023 | 8.558B |
| September 30, 2023 | 7.528B |
| June 30, 2023 | 8.059B |
| March 31, 2023 | 8.025B |
| December 31, 2022 | 8.194B |
| September 30, 2022 | 9.484B |
| June 30, 2022 | 9.26B |
| March 31, 2022 | 9.305B |
| December 31, 2021 | 9.171B |
| September 30, 2021 | 9.107B |
| June 30, 2021 | 8.946B |
| March 31, 2021 | 9.074B |
| December 31, 2020 | 8.985B |
| September 30, 2020 | 9.50B |
| June 30, 2020 | 9.553B |
| Date | Value |
|---|---|
| March 31, 2020 | 9.163B |
| December 31, 2019 | 9.402B |
| September 30, 2019 | 8.781B |
| June 30, 2019 | 8.742B |
| March 31, 2019 | 8.811B |
| December 31, 2018 | 8.503B |
| September 30, 2018 | 8.773B |
| June 30, 2018 | 8.851B |
| March 31, 2018 | 8.794B |
| December 31, 2017 | 8.972B |
| September 30, 2017 | 9.054B |
| June 30, 2017 | 9.039B |
| March 31, 2017 | 9.167B |
| December 31, 2016 | 9.039B |
| September 30, 2016 | 8.927B |
| June 30, 2016 | 8.893B |
| March 31, 2016 | 8.909B |
| December 31, 2015 | 8.935B |
| September 30, 2015 | 9.00B |
| June 30, 2015 | 8.923B |
| March 31, 2015 | 8.937B |
| December 31, 2014 | 9.364B |
| September 30, 2014 | 9.323B |
| June 30, 2014 | 9.451B |
| March 31, 2014 | 9.474B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Roche Holding AG | 15.04B |
| AstraZeneca PLC | 14.21B |
| Johnson & Johnson | 15.06B |
| Eli Lilly & Co. | 14.60B |
| Merck & Co., Inc. | 27.26B |